retta and klow BLEND – Research Peptide Retatrutide and KLOW are the

Participants in the CO-MED trial were under medication for one of three pharmacological treatments, including escitalopram monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination

For quantifying cell death, 50,000 HCC-1806 cells were seeded into 6-well plates and treated as indicated

Acknowledgments We would like to thank TW for providing the experimental platform (Research Center for High Altitude Medicine, Qinghai University) and Editage (www.editage.cn) for English language editing

Nanoparticle-based delivery systems The therapeutic application of PRLMs in chronic inflammatory diseases is limited by their restricted tissue-targeting capacity